• The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
  • Subscribe
  • Sign in
  • Pharma
  • Medtech
  • Biotech
  • Science
  • Events
  • Careers
  • Jobs
  • Opinion & Debate
  • The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
Menu
  • Subscribe
  • Sign in
Clinical Trials

Bavarian Nordic initiates Phase 2 trial

Malin Otmani

-

March 27, 2018

Share article on X
Share article on Linkedin


Published: March 27, 2018

Top stories

Funding – April 29, 2026

Ulf Landegren and his family create research foundation

Through a donation, a new foundation has been formed called Familjen Landegrens stiftelse för medicinsk forskning (Landegren Family Foundation for Medical Research). The purpose of this foundation is to support Uppsala University’s medical research and medical innovation.

Sweden – April 29, 2026

Stockholm Science City’s Ylva Williams sees a more integrated life science region emerging

Once a fragmented landscape of strong research but limited cohesion, Stockholm’s life science ecosystem is now accelerating toward a more integrated future – a shift that Stockholm Science City’s CEO Ylva Williams has helped drive over nearly two decades.

Uncategorized – April 29, 2026

Tortugas Neuroscience launches with USD 106 million for mid‑stage brain drugs

The US‑based company has debuted in combined seed and Series A financing to advance a portfolio of mid‑stage neurology and neuropsychiatry drugs in‑licensed from Eisai and Hansoh.

Financing – April 28, 2026

Ray Therapeutics raises USD 125 million, Novo Holdings doubles down on optogenetic eye gene therapy

The US company has closed an upsized, oversubscribed Series B to advance its optogenetic gene therapy pipeline for blinding retinal diseases with Novo Holdings reinforcing a strong Nordic investment footprint in late‑stage ophthalmology.
Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Related posts

Clinical Trials - April 24, 2026

Takeda reports additional Phase 3 clinical insights on TAK-279

Takeda has announced new data, presented at the 2026 American Academy of Dermatology (AAD), from two Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).

Clinical Trials - April 22, 2026

Hemispherian initiates Phase 1/2a clinical trial

The company has announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.

Clinical Trials - April 22, 2026

Lytix Biopharma announces Phase II results

The company has announced final efficacy and safety results from its Phase II ATLAS-IT-05 study evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with advanced melanoma who have progressed following prior checkpoint inhibitor therapy.

Clinical Trials - April 21, 2026

Novo Nordisk’s etavopivat met both co-primary endpoints in phase 3 trial

The company has announced the topline results from HIBISCUS, a phase 3 trial of once-daily oral etavopivat in adults and adolescents with sickle cell disease (SCD).

Clinical Trials - April 19, 2026

Evaxion’s AI-Immunology platform demonstrates 86% vaccine target precision

Evaxion has announced new data demonstrating that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets.

Clinical Trials - April 15, 2026

Promising results about new Lyme disease vaccine candidate

Pfizer and Valneva's Lyme disease vaccine candidate demonstrated strong efficacy in their Phase 3 VALOR trial.

Clinical Trials - April 13, 2026

Mendus starts clinical program in chronic myeloid leukemia

The company has completed preparations and received all regulatory approvals for the VITAL-CML trial.

Sign up to our Newsletter!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

The leading life science news channel in the Nordic region.

© NLS Media Group AB – All rights reserved

Digital and print
  • The magazine
  • Subscribe
  • Newsletter
More information
  • About us
  • Contact
  • Advertising
Social media
  • LinkedIn
  • Bluesky
  • X
NLS Media Group AB

St Paulsgatan 13

118 46 Sweden

info@nlsnews.com

+46-8-588 941 51

  • Cookies
  • Data management and privacy policy

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.